MedTrace Logo

HD-tDCS: Effects on the Somatosensory System

NCT04165876 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2020-06-11

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy of high definition tDCS on different cortical targets in modulating the nociceptive system in the healthy subjects.

Conditions

  • Acute Pain
  • Neuroplasticity
  • Brain Modulation
  • Somatosensory Function

Interventions

DEVICE

Primary Motor Cortex Stimulation

Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of primary motor cortex (M1) using a ring-cathode configuration

DEVICE

Dorsolateral Prefrontal Cortex Stimulation

Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal stimulation of dorsolateral prefrontal cortex (DLPFC) using a ring-cathode configuration

DEVICE

Multimodal Stimulation (DLPFC+M1)

Using the Starstim 32, HD-tDCS equipment we provide 20 minutes of 2 mA anodal multimodal stimulation of dorsolateral prefrontal cortex (DLPFC) and primary motor cortex simultaneously using ring-cathode configurations around the two anodes.

DEVICE

Sham stimulation

Using the Starstim 32, HD-tDCS equipment we provide sham stimulation with 30 seconds of ramping up to 2 mA intensity, then turning off for 19 minutes and then ramping down from 2 mA intensity to 0 in the last 30 seconds.

Sponsors & Collaborators

  • Danish National Research Foundation

    collaborator OTHER

  • Aalborg University

    lead OTHER

Principal Investigators

  • Thomas Graven-Nielsen, Prof. · Aalborg University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-18
Primary Completion
2020-02-18
Completion
2020-03-18

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04165876 on ClinicalTrials.gov